Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

LIPOSOME CO. HALTS MAITEC LIPOSOMAL GENTAMICIN DEVELOPMENT

  • News

Executive Summary

LIPOSOME CO. HALTS MAITEC LIPOSOMAL GENTAMICIN DEVELOPMENT worldwide "to focus the company's resources on its other products," the Princeton, N.J. liposome encapsulation company reported Feb. 23. The Liposome Company previously had announced at the Wheat First/Butcher & Singer health care conference Oct. 26 that Phase III trials of its liposomal gentamicin for Mycobacterium avium intracellulare in AIDS patients would begin in "several months" ("The Pink Sheet" Nov. 8, 1993, T&G-5). At the time, a Phase IIb trial was under way in the U.S. and a Phase III trial was ongoing in Europe. All developmental efforts have now been "suspended."

Table

View full table

Tags:
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS024102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By